Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12332730 | PMC |
| http://dx.doi.org/10.21037/qims-24-2445 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dual-focal-spot single-detector CT: A simulation study to assess cone-beam artifacts and noise.
J Appl Clin Med Phys
September 2025
Department of Radiology, Emory University School of Medicine, Atlanta, Georgia, USA.
Background: Ultra-wide coverage CT (> 128 detector rows) makes it possible to image a heart or brain in a single rotation but are associated with large cone angles, which can severely degrade the image quality.
Purpose: This study evaluate the image quality and artifact levels of a dual-focal-spot single-detector (DFSSD) CT geometry designed to achieve 140 mm z-axis coverage, through a simulation study.
Methods: The DFSSD CT system employs two x-ray focal spots spaced 90 mm apart along the z-axis and a 100 mm CT detector.
ProSPective evaluation of the dIagnostic accuracy of siNe spiN non-contrast flatdEtectoR CT (FDCT) for the detection of intracranial hemorrhage in stroke patients - Protocol of a non-inferiority comparison to multi detector CT.
PLoS One
August 2025
Department of Neurosurgery, Semmes Murphey Clinic and University of Tennessee Health Sciences Center, Memphis, Tennessee, United States of America.
Rationale: Whether syngo DynaCT Sine Spin non-contrast flat detector CT (FDCT) imaging is sufficient to rule out intracranial hemorrhage in suspected acute stroke patients is unknown.
Aim: To determine if syngo DynaCT Sine Spin non-contrast FDCT imaging is non-inferior to conventional multidetector CT (MDCT) imaging for the detection and exclusion of intracranial hemorrhages in suspected acute stroke patients.
Sample Size: To enroll 252 participants in three buckets (126 ischemic stroke patients, 126 hemorrhagic stroke patients (including 14 patients with an isolated infratentorial hemorrhage).
The Association of Adropin with Asymptomatic Coronary Calcification in Patients in Early Stages of Chronic Kidney Disease.
Int J Mol Sci
August 2025
Department of Internal Medicine and Nephrology, VitaCenter, 69000 Zaporozhye, Ukraine.
Early stages of chronic kidney disease (CKD) are closely associated with vascular remodeling and coronary artery calcification. The aim of this study is to determine whether adropin is associated with asymptomatic coronary calcification in patients in the early stages of CKD. This study enrolled 337 individuals fulfilling the inclusion criteria of the early stages of CKD (G1-2, A1-3) and divided them into two subgroups with ( = 196) and without ( = 141) asymptomatic coronary artery calcification.
View Article and Find Full Text PDFDevelopment and validation of a CT-based multi-omics nomogram for predicting hospital discharge outcomes following mechanical thrombectomy.
Front Neurosci
August 2025
Department of Neurology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Objective: This study aimed to develop a multi-omics nomogram that combines clinical parameters, radiomics, and deep transfer learning (DTL) features of hyperattenuated imaging markers (HIM) from computed tomography scans immediately following mechanical thrombectomy (MT) to predict functional outcomes at discharge.
Methods: This study enrolled 246 patients with HIM who underwent MT. Patients were randomly assigned to a training cohort ( = 197, 80%) and a validation cohort ( = 49, 20%), with an additional internal prospective test cohort ( = 57).
Longitudinal Computed Tomography Indicates No Negative Impact of OnabotulinumtoxinA on Mandibular Bone Density in a 12-Month, Double-Blind, Randomized, Repeat Treatment, Placebo-Controlled Study in Healthy Adults With Masseter Muscle Prominence.
Aesthet Surg J
August 2025
Botox and neurotoxins, Allergan Aesthetics, an AbbVie company, Irvine, CA, USA.
Background: Botulinum neurotoxins are used to treat masseter muscle prominence (MMP), benign bilateral masseter muscle enlargement which can be aesthetically undesirable. Limited data report botulinum neurotoxin injections in the muscles of mastication, with subsequent reduction in biomechanical loading, may impact mandibular bone density.
Objectives: This study evaluates whether changes in mandibular bone density occur after bilateral masseter treatment with a botulinum neurotoxin, onabotulinumtoxinA, in individuals with MMP.